About Index Trending news
Analyze
Top 50 Pricing
Inovio Pharmaceuticals

Inovio Pharmaceuticals

Work at Inovio Pharmaceuticals? Add yourself to this profile

Inovio Pharmaceuticals

Elsewhere

Alexa global traffic share

Latest funding
Grant
$45,000,000
Employees

Unknown size

The Motley Fool

How Inovio Pharmaceuticals Is Leading the Zika Vaccine Race

The Motley Fool

Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward

The Motley Fool

Why Inovio Pharmaceuticals Inc. Is Soaring Today

The Motley Fool

1 Big Reason Why Inovio Pharmaceuticals, Inc. Was All the Buzz in April

The Motley Fool

Better Buy: Inovio Pharmaceuticals Inc. vs. Novavax Inc.

The Motley Fool

Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?

The Motley Fool

3 Reasons Why Inovio Pharmaceuticals, Inc. Was Unstoppable in March

The Motley Fool

Inovio Pharmaceuticals Won't Move Forward With Clinical Study: So What?

The Motley Fool

Better Buy: Inovio Pharmaceuticals Inc. vs. Juno Therapeutics

The Motley Fool

Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation

The Motley Fool

Is Inovio Pharmaceuticals' Zika Surge Premature?

The Motley Fool

2 Reasons Behind Inovio Pharmaceuticals, Inc.'s Tumble in 2015 --

The Motley Fool

Will 2016 Be Inovio Pharmaceuticals, Inc.'s Best Year Yet? (INO)

The Motley Fool

The Worst Inovio Pharmaceuticals, Inc. Headlines in 2015 --

The Motley Fool

The 3 Most Important Drugs in Inovio Pharmaceuticals' Pipeline --

Health Stock markets
The Motley Fool

Inovio Pharmaceuticals Produces a Rare Quarterly Profit, but Don't Get Too Excited Just Yet --

Health Stock markets Earnings
The Motley Fool

Here's Why Inovio Pharmaceuticals Had the Cure for Investors' Ills in October --

The Motley Fool

Is Inovio Pharmaceuticals a Late Bloomer? --

Health Stock markets Science